Orchid Pharma-Dhanuka Laboratories merger takes effect on July 10, 2026
AI Market Summary
Orchid Pharma's NCLT-sanctioned merger with Dhanuka Laboratories is now effective, consolidating assets and expanding authorized capital, with a July 23 record date and a 161:5 share-swap ratio. Separately, an exclusive licensing and supply deal with Russia's Pharmasyntez for Exblifep (potential USD 178m over 10 years, subject to regulatory approvals) strengthens international commercialization optionality. Near-term market impact is mostly idiosyncratic to the issuer.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.24%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Orchid Pharma’s merger scheme with Dhanuka Laboratories became effective on July 10, 2026, resulting in Dhanuka Laboratories being dissolved and all its assets, liabilities and business transferring to Orchid Pharma. Following the amalgamation, Orchid Pharma’s authorized share capital increased to ₹164,51,00,000 and the company set July 23 as the record date for issuing shares under a 161:5 exchange ratio (face value ₹10:₹100). Orchid Pharma also said it has signed an exclusive supply agreement with Russia’s Pharmasyntez for Exblifep, with a potential value of USD 178 million.
